GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » St Jude Medical Inc (NYSE:STJ) » Definitions » ROE %

St Jude Medical (St Jude Medical) ROE % : 19.35% (As of Sep. 2016)


View and export this data going back to 1977. Start your Free Trial

What is St Jude Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. St Jude Medical's annualized net income for the quarter that ended in Sep. 2016 was $848 Mil. St Jude Medical's average Total Stockholders Equity over the quarter that ended in Sep. 2016 was $4,384 Mil. Therefore, St Jude Medical's annualized ROE % for the quarter that ended in Sep. 2016 was 19.35%.

The historical rank and industry rank for St Jude Medical's ROE % or its related term are showing as below:

STJ's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.31
* Ranked among companies with meaningful ROE % only.

St Jude Medical ROE % Historical Data

The historical data trend for St Jude Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

St Jude Medical ROE % Chart

St Jude Medical Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.67 17.55 17.37 23.77 21.36

St Jude Medical Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.94 11.25 9.34 22.72 19.35

Competitive Comparison of St Jude Medical's ROE %

For the Medical Devices subindustry, St Jude Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


St Jude Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, St Jude Medical's ROE % distribution charts can be found below:

* The bar in red indicates where St Jude Medical's ROE % falls into.



St Jude Medical ROE % Calculation

St Jude Medical's annualized ROE % for the fiscal year that ended in Dec. 2015 is calculated as

ROE %=Net Income (A: Dec. 2015 )/( (Total Stockholders Equity (A: Dec. 2014 )+Total Stockholders Equity (A: Dec. 2015 ))/ count )
=880/( (4199+4042)/ 2 )
=880/4120.5
=21.36 %

St Jude Medical's annualized ROE % for the quarter that ended in Sep. 2016 is calculated as

ROE %=Net Income (Q: Sep. 2016 )/( (Total Stockholders Equity (Q: Jun. 2016 )+Total Stockholders Equity (Q: Sep. 2016 ))/ count )
=848/( (4281+4486)/ 2 )
=848/4383.5
=19.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2016) net income data. ROE % is displayed in the 30-year financial page.


St Jude Medical  (NYSE:STJ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2016 )
=Net Income/Total Stockholders Equity
=848/4383.5
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(848 / 5996)*(5996 / 12599.5)*(12599.5 / 4383.5)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.14 %*0.4759*2.8743
=ROA %*Equity Multiplier
=6.73 %*2.8743
=19.35 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2016 )
=Net Income/Total Stockholders Equity
=848/4383.5
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (848 / 980) * (980 / 1144) * (1144 / 5996) * (5996 / 12599.5) * (12599.5 / 4383.5)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8653 * 0.8566 * 19.08 % * 0.4759 * 2.8743
=19.35 %

Note: The net income data used here is four times the quarterly (Sep. 2016) net income data. The Revenue data used here is four times the quarterly (Sep. 2016) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


St Jude Medical ROE % Related Terms

Thank you for viewing the detailed overview of St Jude Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


St Jude Medical (St Jude Medical) Business Description

Traded in Other Exchanges
N/A
Address
St Jude Medical Inc was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician pro
Executives
Jeff Fecho officer: VP, Global Quality ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Philip Ebeling officer: VP, Chief Technology Officer INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BLVD., SUITE 1600, GOLDEN VALLEY MN 55416
Donald Zurbay officer: VP Finance and CFO C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Michael A Rocca director C/O LIGAND PHARMACEUTICALS INCORPORATED, 10275 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Barbara B Hill director
Wendy L Yarno director
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John C Heinmiller officer: Executive Vice President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
John W Brown director STRYKER CORP, 2725 FAIRFIELD ROAD, KALAMAZOO MI 49002
David C Dvorak director C/O ZIMMER INC, PO BOX 708, WARSAW IN 46580
Michael T Rousseau director, officer: Director, President and CEO ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Eric S Fain officer: Group President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Joel Becker officer: President, Americas ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Rohan Hoare officer: President - NMD 100 CYBERONICS BLVD, HOUSTON TX 77058